Hans T. Schambye

This profile gathers the share dealings of Hans T. Schambye in Damora Therapeutics, Inc., where the filings describe the role as chief executive. Over a trading history stretching from 24 June 2021 to 2 January 2026, the count stands at 6 filings.

No open-market sale appears; the market trades are 3 purchases worth €36k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 3 option exercises.

A typical purchase (the median) is worth €13k. Clusters matter here: 3 out of 3 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster.

The record was last updated on 6 January 2026 with an option exercise in Damora Therapeutics, Inc. The last insider purchase was made public on 23 March 2022, 1,670 days ago. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.